| Literature DB >> 28493922 |
B Gareb1, N B van Bakelen1, G J Buijs1, J Jansma1, J G A M de Visscher2, Th J M Hoppenreijs3, J E Bergsma4, B van Minnen1, B Stegenga1,5, R R M Bos1.
Abstract
BACKGROUND: Biodegradable fixation systems could reduce or eliminate problems associated with titanium removal of implants in a second operation. AIM: The aim of this study was to compare the long-term (i.e. >5 years postoperatively) clinical performance of a titanium and a biodegradable system in oral and maxillofacial surgery.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28493922 PMCID: PMC5426637 DOI: 10.1371/journal.pone.0177152
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Inclusion and exclusion criteria.
| - patients scheduled for a Le Fort-I fracture, and/or a solitary or multiple (maximum 2) mandibular fracture(s), and/or a zygoma fracture; |
| - patients scheduled for a Le Fort-I osteotomy, and/or a Bi-lateral Sagittal Split Osteotomy (BSSO); |
| - patients (also parents or responsible persons if necessary) who signed the |
| - patients who were younger than 18 years old (trauma), or patients who were younger than 14 years (osteotomies); |
| - patients presented with heavily comminuted fractures of the facial skeleton; |
| - patients who experienced compromised bone healing in the past; |
| - patients who were pregnant; |
| - patients who could/would not participate in a 1-year follow-up (reasons); |
| - patients who would not agree with an |
| - patients who were diagnosed with a psychiatric disorder (diagnosed by a psychiatrist); |
| - patients who experienced cleft lip and palate surgery in the past; |
| - patients where fracture reduction and fixation was delayed for more than 7 days (after day of trauma); |
| - patients of whom the general health and/or medication could affect bone healing, as determined by the oral and maxillofacial surgeon. |
Fig 1Flow diagram of patient’s progress through the phases of RCT.
* Plate removal analyses. † Analyses of the other variables. ITT = intention-to-treat, n = number.
Baseline characteristics of the total included and telephonically contacted patients.
| Description | Total included patients | Contacted patients | ||||
|---|---|---|---|---|---|---|
| Titanium (n) | Biodegradable (n) | P-value | Titanium (n) | Biodegradable (n) | P-value | |
| 134 | 87 | 85 | 56 | |||
| BSSO | 87 (64.9%) | 55 (66.3%) | 0.795 | 59 (69.4%) | 35 (62.5%) | 0.165 |
| Le Fort-I osteotomy | 8 (6.0%) | 8 (9.2%) | 3 (3.5%) | 5 (8.9%) | ||
| Bi-maxillary osteotomy | 29 (21.6%) | 16 (18.4%) | 19 (22.4%) | 11 (19.6%) | ||
| Mandibular fracture | 6 (4.5%) | 4 (4.6%) | 4 (4.7%) | 2 (3.6%) | ||
| Le Fort-I fracture | 1 (0.7%) | 0 | 0 | 0 | ||
| Zygoma fracture | 3 (2.2%) | 4 (4.6%) | 0 | 3 (5.4%) | ||
| Male | 55 (41%) | 43 (49.4%) | 0.268 | 37 (43.5%) | 28 (50%) | 0.492 |
| Female | 79 (59%) | 44 (50.6%) | 48 (56.5%) | 28 (50%) | ||
| Age (median (range) in years) | 29 (16–60) | 28 (14–59) | 0.786 | 30 (16–60) | 30 (15–59) | 0.993 |
*Analyses performed on all included patients, without the Protocol violations and the Treatment Received violations(see Fig 1), n = 221: titanium n = 134, biodegradable n = 87).
†Tested two-tailed.
‡ Analyses performed on all telephonically contacted patients after long-term follow-up (i.e. >5 years postoperatively), n = 141: titanium n = 85, biodegradable n = 56).
Abbreviations: BSSO = bilateral-sagittal-split osteotomy, n = number.
Outcome measures after long-term follow-up (i.e. >5 years post-operatively).
| Description | Titanium (n) | Biodegradable (n) | P-value |
|---|---|---|---|
| 22/134 (16.4%) | 23/87 (26.4%) | 0.036 | |
| | 0.318 | ||
| | 19/124 (15.3%) | 23/79 (29.1%) | |
| BSSO | 14/87 (16.1%) | 19/55 (34.5%) | |
| Le Fort-I osteotomy | 0/8 | 0/8 | |
| Bi-maxillary osteotomy | 5/29 (17.2%) | 4/16 (25%) | |
| | 3/10 (30.0%) | 0/8 | |
| Mandibular fracture | 2/6 (33.3%) | 0/4 | |
| Le Fort-I fracture | 0/1 | 0/0 | |
| Zygoma fracture | 1/3 (33.3%) | 0/4 | |
| Non-correct occlusion | 14 (16.5%) | 6 (10.7%) | 0.461 |
| Palpability plate/screws | 34 (41.5%) | 4 (7.8%) | < 0.001 |
| Swelling | 3 (3.5%) | 4 (7.1%) | 0.436 |
| Permanent | 2 (2.4%) | 3 (5.4%) | |
| Fluctuating | 1 (1.2%) | 1 (1.8%) | |
| Pain VAS (median (range)) | 0 (0–80) | 0 (0–80) | 0.736 |
| MFIQ (median (range)) | 18 (17–64) | 17 (17–71) | 0.110 |
| Content with surgical procedure | 81 (95.3%) | 51 (91.1%) | 0.483 |
| 95 (77–111) | 98 (80–111) | 0.458 |
*Tested two-tailed.
†Analyses performed on all included patients, without the Protocol violations and the Treatment Received violations (see Fig 1), n = 221: titanium n = 134, biodegradable n = 87).
‡ After adjusting for intra-operative switches. Univariable plate removal analysis showed no significant difference between both subgroups (P = 0.070).
¶ Analyses performed on all telephonically contacted patients after long-term follow-up (i.e. >5 years postoperatively), n = 141: titanium n = 85, biodegradable n = 56).
#The patients in whom the plates/screws were removed were not included in the analysis.
||The mandibular function was evaluated by the 17 questions of the MFIQ [1]; range 17–85; a higher score means worse function.
● The follow-up of all telephonically contacted patients. The follow-up of all included patients was 98 (78–113) months.
Abbreviations: BSSO = bilateral-sagittal-split osteotomy, MFIQ = Mandibular Function Impairment Questionnaire, n = number, VAS = Visual Analogue Scale (range 0–100).
Fig 2Kaplan-Meier curve of plate removal after long-term follow-up of all included patients (n = 221: titanium n = 134, biodegradable n = 87).
Adjusted hazard ratio (HR) biodegradable = 2.0 (95% CI: 1.05–3.8), HR titanium = 1; p = 0.036.